Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by University of Illinois at Chicago
University of Illinois at Chicago
Information provided by (Responsible Party):
Julio Duarte, University of Illinois at Chicago Identifier:
First received: January 24, 2014
Last updated: May 28, 2015
Last verified: May 2015
Heart failure with preserved ejection fraction (HFpEF), is one of the leading causes of pulmonary hypertension (PH). Despite the severity of this disease, no established treatments exist for this class of PH. Nebivolol is a drug used in high blood pressure and heart failure, but not used in patients with PH. Due to some additional properties it possesses, the investigators believe nebivolol will improve disease severity in patients with with PH associated with HFpEF. This project will be a prospective, open-label 18-week clinical study of nebivolol in patients with PH associated with HFpEF. Patients will be identified in clinic based on echocardiogram (TTE) and right heart catheterization (RHC) results (both part of standard clinical care) indicating PH and HFpEF.

Condition Intervention Phase
Pulmonary Hypertension
Diastolic Heart Failure
Heart Failure With Preserved Ejection Fraction
Drug: Nebivolol
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure

Resource links provided by NLM:

Further study details as provided by University of Illinois at Chicago:

Primary Outcome Measures:
  • Changes in pulmonary vascular pressure [ Time Frame: baseline - 18 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Changes in 6-minute walk distance [ Time Frame: baseline - 18 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: January 2014
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nebivolol Drug: Nebivolol


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults (≥ 18 years of age) with World Health Organization Group 2 Pulmonary Hypertension (Mean pulmonary artery pressure ≥ 25 mmHg and pulmonary capillary wedge pressure ≥ 15 mmHg)
  • A diagnosis of heart failure by a University of Illinois cardiologist
  • New York Heart Association class II-IV symptoms
  • Left ventricular ejection fraction (LVEF) ≥ 45%

Exclusion Criteria:

  • Other causes of heart failure other than diastolic dysfunction, such as restrictive cardiomyopathy or infiltrative cardiomyopathy
  • Active smokers,
  • Women who are pregnant or nursing
  • Liver cirrhosis,
  • Primary valvular disease
  • Acute coronary syndrome
  • Causes of PH other than that of heart failure, such as: chronic thromboembolic PH, sickle-cell disease, or sarcoidosis
  • Severe renal insufficiency (patient on hemodialysis or serum creatinine > 2.5 mg/dl)
  • Severe bradycardia or greater than 1st degree heart block
  • Decompensated heart failure
  • Current use of a third generation beta-blocker (nebivolol, carvedilol, or labetalol) or high dose of any beta-blockers (greater than 100 mg daily of metoprolol, or equivalent)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02053246

Contact: Julio Duarte, PharmD, PhD (312) 996-7440

United States, Illinois
University of Illinois at Chicago Recruiting
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Julio Duarte
University of Illinois at Chicago
Principal Investigator: Julio Duarte, PharmD, PhD University of Illinois at Chicago
  More Information

No publications provided

Responsible Party: Julio Duarte, Assistant Professor, University of Illinois at Chicago Identifier: NCT02053246     History of Changes
Other Study ID Numbers: 2012-0824 
Study First Received: January 24, 2014
Last Updated: May 28, 2015
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Heart Failure
Heart Failure, Diastolic
Hypertension, Pulmonary
Cardiovascular Diseases
Heart Diseases
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Adrenergic Agents
Adrenergic Antagonists
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasodilator Agents processed this record on February 04, 2016